ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.Scandinavian journal of urology · 2018Trial
- Persuasive Interventions for Controversial Cancer Screening Recommendations: Testing a Novel Approach to Help Patients Make Evidence-Based Decisions.Annals of family medicine · 2017Trial
- The prevalence and predictors of previous prostate cancer screening among men attending primary healthcare centers in Riyadh, Saudi Arabia.Annals of medicine · 2026Article
- Article
- Individual and Socioeconomic Affecting Factors for Prostate Cancer Screening Behavior.The world journal of men's health · 2025Review
- Determinants of Prostate Cancer Screening in Korean Men: A Nationwide Study Using the Korean National Cancer Screening Survey 2023.Cancer research and treatment · 2025Article
- Chronological Trends of PSA Levels at Diagnosis in Population-based Prostate Cancer Data 2004-2021, a Time Period of Drastic Changes in Screening Guidelines: Potential Implications in Prostate Cancer Diagnosis.Journal of registry management · 2025Article
- Over 48,000 baseline prostate-specific antigen measurements in young men: a 16-year time-analysis.Central European journal of urology · 2024Article
- Associations of Content and Context of Communication with Prostate-Specific Antigen Testing.International journal of environmental research and public health · 2023Article
- Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.Cancer reports (Hoboken, N.J.) · 2021Article
- Prostate-specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey data.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Article
- Cancer Progress and Priorities: Prostate Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Are We Choosing Wisely? Older Adults' Cancer Screening Intentions and Recalled Discussions with Physicians About Stopping.Journal of general internal medicine · 2019Article
- Cost implications of PSA screening differ by age.BMC urology · 2018Article
- Screening for prostate cancer: are organized screening programs necessary?Translational andrology and urology · 2018Article
- Stopping screening, when and how?Translational andrology and urology · 2018Review
- Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?European journal of epidemiology · 2017Article
- Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.Prostate cancer and prostatic diseases · 2017Article
- Prostate and Colorectal Cancer Screening Uptake among US and Foreign-Born Males: Evidence from the 2015 NHIS Survey.Journal of community health · 2017Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
purposeFor patients who elect to have prostate cancer screening, the optimal time to discontinue screening is unknown. Our objective was to describe rates and predictors of prostate-specific antigen (PSA) screening among older men in the United States.
methodsData were extracted from the population-based 2000 and 2005 National Health Interview Survey (NHIS). PSA screening was defined as a PSA test as part of a routine exam within the past year. Demographic, socioeconomic, and functional characteristics were collected, and a validated 5-year estimated life expectancy was calculated. Age-specific rates of PSA screening were determined, and sampling weight-adjusted multivariate regressions were fitted to determine predictors of screening among men age 70 years or older.
resultsThe PSA screening rate was 24.0% in men age 50 to 54 years, and it increased steadily with age until a peak of 45.5% among age 70 to 74 years. Screening rates then gradually declined by age, and 24.6% of men age 85 years or older reported being screened. Among men age 70 years or older, screening rates varied by estimated 5-year life expectancy: rates were 47.3% in men with high life expectancies (≤ 15% probability of 5-year mortality), 39.2% in men with intermediate life expectancies (16% to 48% probability), and 30.7% in men with low life expectancies (> 48% probability; P < .001). In multivariate analysis, estimated life expectancy and age remained independently associated with PSA screening (P < .001 for each).
conclusionRates of PSA screening in the United States are associated with age and estimated life expectancy, but excessive PSA screening in elderly men with limited life expectancies remains a significant problem. The merits and limitations of PSA should be discussed with all patients considering prostate cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.